Allergan Plc (AGN)

190.55
0.20 0.10
NYSE : Health Technology
Prev Close 190.75
Open 190.75
Day Low/High 189.20 / 191.39
52 Wk Low/High 142.81 / 237.41
Volume 690.27K
Avg Volume 1.99M
Exchange NYSE
Shares Outstanding 339.44M
Market Cap 63.00B
EPS -13.20
P/E Ratio N/A
Div & Yield 2.88 (1.54%)

Latest News

Aegon Reports Strong First Half 2018 Results

Aegon Reports Strong First Half 2018 Results

Net income amounts to EUR 491 million supported by increase in underlying earnings Underlying earnings increase by 2% to EUR 1,064 million, or 10% on constant currencies driven by expense savings, a higher investment margin in the Netherlands, performance...

Aegon To Divest Its Businesses In Czech Republic And Slovakia

Aegon To Divest Its Businesses In Czech Republic And Slovakia

Aegon has agreed to sell its businesses in Czech Republic and Slovakia for EUR 155 million to NN Group.

Here's What Was Behind Monday's Selloff

The Dow Jones Industrial Average declined by 125 points on Monday.

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon has agreed to divest the last substantial block of its life reinsurance business to SCOR Global Life.

Let Me Report Two of the Oddest Statistics of the Day

The first is the ISE Equity Ratio which chimed in at 213%, its first reading over 200% since January 26.

Following Up on Cimarex

So where do we go from here? We have a rule to never sell into a maelstrom.

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon To Divest Last Block Of US Life Reinsurance Business

Aegon has agreed to divest the last substantial block of its life reinsurance business to SCOR Global Life.

Allergan And Editas Medicine Announce Exercise Of Options To Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Allergan And Editas Medicine Announce Exercise Of Options To Jointly Develop CRISPR Genome Editing Experimental Medicine EDIT-101

Reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Procter & Gamble, Western Digital, Allergan: 'Mad Money' Lightning Round

Jim Cramer weighs in on Procter & Gamble, Six Flags, Western Digital, Allergan, Principal Financial Group.

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Risk and Uncertainty: Cramer's 'Mad Money' Recap (Monday 7/30/18)

Jim Cramer says somebody panicked, and their departure left behind a mess in the tech sector. But that spells a buying opportunity.

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

Netflix and Twitter Are Among 29 Stocks Ready to Change Direction

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

Tech Rotation Hits Market; Bullpen Update

We are looking at today's rotation as an opportunity to pick up a high-quality name at a discount.

Allergan Announces Third Quarter 2018 Cash Dividend Of $0.72 Per Ordinary Share

Allergan Announces Third Quarter 2018 Cash Dividend Of $0.72 Per Ordinary Share

-- Dividend to be Paid on September 17, 2018 --

Allergan Pushes Back on M&A Questions; Comcast Happy With Its Portfolio - ICYMI

Allergan Pushes Back on M&A Questions; Comcast Happy With Its Portfolio - ICYMI

Botox maker Allergan's CEO is pushing back against activist investors and may get help from the company's latest earnings report.

Hated Stocks May Not Always Stay Hated

Recent moves in industrial stocks demonstrate the importance of buying hated stock/groups when your conviction is high.

Allergan Announces $2 Billion Share Buyback Program, Raises Guidance

Allergan Announces $2 Billion Share Buyback Program, Raises Guidance

The drug giant beat analyst expectations for Q2 and issued positive guidance for the rest of the year.

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

3 Best Chip Stocks to Own After AMD's Monster Earnings Beat: Market Recon

Micron Technology, Intel and Lam Research are good buys on this heat in semiconductors.

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

Facebook, Amazon, AMD, Qualcomm and PayPal - 5 Things You Must Know

U.S. stock futures are mixed as investors react with caution to a broadly worded trade truce between the European Union and the United States; Facebook tanks as the social media giant points to slower growth; AMD swings to a profit; Qualcomm scraps deal for NXP.

Allergan Reports Strong Second Quarter 2018 Results Including GAAP Net Revenues Of $4.1 Billion

Allergan Reports Strong Second Quarter 2018 Results Including GAAP Net Revenues Of $4.1 Billion

- Q2 2018 GAAP Loss Per Share of $1.39; Non-GAAP Performance Net Income Per Share of $4.42 -

Allergan Receives FDA Fast Track Designation For AGN-241751 For The Treatment Of Major Depressive Disorder (MDD)

Allergan Receives FDA Fast Track Designation For AGN-241751 For The Treatment Of Major Depressive Disorder (MDD)

- New Molecule Recognized as a Potentially Innovative Treatment for MDD, a Serious Condition with Persistent Unmet Need -

Allergan And Molecular Partners Announce Two Positive Phase 3 Clinical Trials For Abicipar Pegol 8 And 12-week Regimens For The Treatment In Patients With Neovascular Age-Related Macular Degeneration

Allergan And Molecular Partners Announce Two Positive Phase 3 Clinical Trials For Abicipar Pegol 8 And 12-week Regimens For The Treatment In Patients With Neovascular Age-Related Macular Degeneration

Abicipar, the first and only anti-VEGF to maintain stable vision in greater than 91 percent of patients on a fixed 12-week regimen, achieved the primary endpoint of non-inferiority to monthly ranibizumab at week 52

It's All About Expectations: Cramer's 'Mad Money' Recap (Tuesday 7/10/18)

It's All About Expectations: Cramer's 'Mad Money' Recap (Tuesday 7/10/18)

Jim Cramer uses PepsiCo's earnings, which crushed analysts' expectations, to illustrate why investors need to do their own homework to find real winners.

Allergan Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Drops

Allergan Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Drops

- New Artificial Tear Improves Clarity of Vision, Protects The Eye's Surface And Treats The Signs And Symptoms Of Dry Eye -

Aegon And Santander To Expand Successful Partnership In Spain

Aegon And Santander To Expand Successful Partnership In Spain

Aegon today announces that it has signed an agreement to expand its successful partnership with Banco Santander in Spain.

Allergan's Study In Chronic Migraine Receives Migraine Research Award At The American Headache Society's 60th Annual Scientific Meeting

Allergan's Study In Chronic Migraine Receives Migraine Research Award At The American Headache Society's 60th Annual Scientific Meeting

- Award-winning Chronic Migraine epidemiology study (CaMEO) and 17 additional presentations showcase Allergan innovation and leadership in research for migraine treatment and prevention -

Allergan To Report Second Quarter 2018 Earnings And Host Conference Call And Webcast

Allergan To Report Second Quarter 2018 Earnings And Host Conference Call And Webcast

DUBLIN, June 26, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it intends to release second quarter 2018 financial results on Thursday, July 26, 2018, prior to the open of U.

TheStreet Quant Rating: D+ (Sell)